Dr. Vlatko Silobrcic, born in 1935. M.D. (1959) and Ph.D. (1963) degrees: University of Zagreb Medical School. Postdoctoral Fellow: Baylor University College of Medicine, Houston (18 months); Project Investigator: M.D. Anderson Hospital and Tumor Institute, Houston (12 months); Visiting Fellow: Massachusetts General Hospital, Boston (24 months). Professor of Immunology: University of Zagreb Medical School. Research in Transplantation and Tumor Immunology. Published 71 papers in international journals, 75 professional papers, 118 invited lectures, 24 scientific and professional awards. Member, Croatian Academy of Sciences and Arts. Founder and Editor-in-Chief: biomedical journal “Periodicum Biologorum”, Zagreb. General Director: Institute of Immunology, Zagreb (1992–1997). Retired in 1997.

Prof. Dr. Gürkan Ersoy is a distinguished General Surgeon and Emergency Medicine specialist with over 40 years of experience in medical practice, education, disaster management, and healthcare leadership. He graduated from Trakya University Faculty of Medicine in 1984 and completed his specialization in General Surgery at Sivas Cumhuriyet University in 1991. Throughout his academic career at Dokuz Eylül University, he earned the titles of Assistant Professor, Associate Professor, and Professor, while also serving in several leadership positions, including Founding Acting Dean of the Faculty of Health Sciences and Director of the Academic Emergency Medicine and Disaster Education Center (ATAMER). Prof. Ersoy received advanced training in emergency medicine, trauma surgery, and disaster management in Israel and the United States. He has authored nearly 100 scientific publications, contributed to 15 academic books, and participated in over 500 scientific congresses and educational programs. Currently, he serves as a lecturer at International Cyprus University and a Visiting Lecturer at İzmir Tınaztepe University, with a growing focus on Artificial Intelligence applications in medicine.

Dr. Sveta Mikhlin is a Developer and researcher of veterinary vaccines for poultry, Biovac, Israel. Participated in the development of live and inactivated vaccines against infectious bronchitis, low-pathogenic avian influenza (H9N2), salmonellosis, fowl cholera, infectious rhinotracheitis, fowl adenovirus hepatitis, and others. PhD in veterinary pharmacology and toxicology since 1989. Received the veterinary qualifications in 1977 from the Veterinary Academy in St. Petersburg, Russia.

Dr. Frederick Wittke is a physician, clinical researcher, and co founder of Arthama GmbH, a Switzerland based platform advancing modern vaccine clinical development through scientific clarity and high quality education. With nearly 30 years of experience across vaccines, infectious diseases, oncology, and immunology, he has held leadership roles at MSD, Debiopharm, Novartis, and GSK, guiding cross functional development teams and global programme strategy. He has contributed to the successful development of several major vaccines and monoclonal antibodies — including Capvaxive, Vaxneuvance, Gardasil 9, Varivax, Vaxelis, and clesrovimab — supporting clinical strategy, study design, and evidence generation across early and late phase development. Dr. Wittke is the author of over 100 peer reviewed publications, with work appearing in The Lancet Infectious Diseases, npj Vaccines, and the American Journal of Obstetrics & Gynecology. His scientific contributions span maternal immunization, pneumococcal vaccines, viral diseases, and immune mediated conditions. Through Arthama, he integrates clinical science, statistical reasoning, and programme architecture to help teams avoid structural pitfalls in biologics development. He is recognised for a clear, modern approach to clinical development — combining scientific depth with operational realism.

Dr. Osama Ibrahim is a distinguished microbiologist, biochemist, and biotechnology expert with extensive experience in microbiology, molecular biology, food safety, bioprocessing, and pharmaceutical research. He earned his Ph.D. in Basic Medical Science from New York Medical College and has led innovative research in microbial screening, fermentation technology, therapeutic proteins, enzymes, and food biotechnology. Following his retirement from Kraft Foods Research Center, he founded Bio Innovation, providing biotechnology consulting to startup companies. Dr. Ibrahim holds multiple patents, has authored numerous scientific publications, and serves on editorial boards and international conference panels. He was recognized in the U.S. Marquis Who's Who Honored Listee 2024 for his contributions to microbiology.

Dr. Pongsak Rattanachaikunsopon is a Professor in the Department of Biological Science at Ubon Ratchathani University, Thailand. He obtained Bachelor of Science in Radiological Technology at Mahidol University, Thailand and a Master of Science in Anatomy at Mahidol University, Thailand. He earned Ph.D. in Molecular Biology at Lehigh University, Pennsylvania USA. He has been awarded with Professor Sood Saengvichain Award for Best Research and Presentation in 13th Annual Meeting of the Society of Anatomy of Thailand in 1990, Professor Dr. Tab Nilanidhi Foundation Award for the outstanding graduate student in Anatomy in 1991 and Best Government Officer, The Ministry of Education in 2014. He serves as an Editorial board member of more than 10 international Journals.

Dr. Graeme Ladds has worked in the field of global Pharmacovigilance for the last 35 years. In that time he has worked with many different product types both in the clinical and post-marketing phase which has included vaccines since 1994. Graeme has developed a number of systems to enhance patient safety including for vaccines as well as ensuring that whatever the volumes of uptake globally for vaccines and for monitoring the data was accurate and complete.

Dr. Cynthia N. Brysch, PhD, is an award-winning global expert in Quality Assurance and Regulatory Affairs, specializing in AI-enabled clinical development, regenerative medicine, and advanced therapeutics. As Vice President and Chief Operating Officer at Devine Guidance International (DGII), she leads global QA/RA strategy, clinical quality oversight, and regulatory remediation across biotech, pharmaceutical, and medical device programs. With over 20 years of experience and more than 500 product development campaigns, Dr. Brysch is known for translating complex innovations—including cell and gene therapies, CRISPR technologies, and AI-integrated clinical systems—into compliant, inspection-ready programs. An FDA Lead Assessor, ICH committee member, ISO accrediting authority, and CAP Inspector, she is recognized for her “science-to-compliance” approach, enabling safe and globally harmonized therapeutic advancements.